NCT01951235View on ClinicalTrials.gov

A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Imeglimin

DRUG

Placebo

Trial Locations (1)

Unknown

Pauls Stradins Clinical University Hospital, Riga

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY